Treats infections caused by susceptible strains of the designated organisms in the…. ANDA 61904, held by Carnegie. Erythromycin Ethylsuccinate.
As of Nov 16, 2026, ANDA 61904 (Erythromycin Ethylsuccinate), held by Carnegie, was first approved by FDA on Mar 3, 1975, with 11 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets, USP and other antibacterial drugs, erythromycin ethylsuccinate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 3, 1975 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Erythromycin EthylsuccinateEQ 400MG BASE · tablet;oral | Erythromycin Ethylsuccinate | Rx |
| Jan 17, 2020 | Supplement 25Labeling · Standard review | Approved | None posted |
| Jan 17, 2020 | Supplement 23Labeling · Standard review | Approved | None posted |
| Dec 4, 2013 | Supplement 21Labeling · Standard review | Approved | |
| Jul 24, 2013 | Supplement 22Labeling · Standard review | Approved | None posted |
| Sep 18, 2009 | Supplement 18Labeling | Approved | None posted |
| Mar 15, 2007 | Supplement 14Labeling | Approved | None posted |
| Jan 3, 2003 | Supplement 12Manufacturing | Approved | None posted |
| May 24, 2001 | Supplement 11Labeling | Approved | None posted |
| Apr 20, 1998 | Supplement 10Manufacturing | Approved | None posted |
| Jul 18, 1989 | Supplement 5Manufacturing | Approved | None posted |
| Aug 29, 1988 | Supplement 8Manufacturing | Approved | None posted |
| Mar 3, 1975 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters